FamiCord Group
- Company typePrivate
- Founded2002
- HeadquartersWarsaw, Poland
- Headcount101–250
- GTM typeB2B and B2C
- OfferingServices
FamiCord Group firmographics
Firmographics- Name
- FamiCord Group
- Legal name
- FamiCord AG
- Website
- https://famicord.eu
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
FamiCord Group industry classification
Industry- Product category
- Stem Cell Banking and Cell Therapy Services
- NAICS
- Blood and Organ Banks (621991), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell Therapy CDMO (HLAGABAD)
- akta.pro secondary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
Keywords
Where FamiCord Group is headquartered
LocationHeadquarters
- HQ city
- Warsaw
- HQ country
- Poland
- HQ region
- Europe
Offices1 record
Markets served
FamiCord Group business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Family Stem Cell Banking Services: Cord blood and tissue banking services for families, including collection, processing, testing, and long-term storage. Revenue is generated through initial banking fees and ongoing storage fees.
- CDMO Services for Biotech and Pharma: Contract development and manufacturing organization services for biotech companies and clinics developing cell-based therapies. Includes process development, tech transfer, cGMP manufacturing, and analytics.
- Expanded Access Programme: Clinical application services providing stem cell therapies to patients through controlled access programs, bridging research to real-world application.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
FamiCord Group product offering
Product offeringCore offering
FamiCord Group is Europe's leading stem cell bank, collecting, processing, testing, and cryogenically storing umbilical cord blood, cord tissue, and placenta tissue for families. The company also operates as a Contract Development and Manufacturing Organization (CDMO) for biotech companies and clinics, providing process development, tech transfer, cGMP manufacturing, analytics, and global logistics for cell therapy Advanced Therapy Medicinal Products (ATIMPs).
Product overview
FamiCord Group operates as Europe's leading stem cell bank, offering a portfolio of cell banking services centered on preserving perinatal cells and tissues. The core family-focused offering includes Stem Cells Banking (umbilical cord blood and tissue collection and storage) and Stem Cells preservation services. The company also provides an Expanded Access Programme for patients seeking experimental cell therapies outside clinical trials. For biotech companies and clinics, FamiCord offers CDMO services for cell therapy ATIMPs, encompassing process development, cGMP manufacturing, and global logistics. The portfolio spans family banking services and business-to-business contract manufacturing services.
Differentiator
Problem solved
Functional benefit
Brands
- PBKM: Stem cell bank brand, evidenced by logo on website and partnership with pbkm.pl in Poland
Products and services
- Stem Cells Banking Collection and long-term cryogenic storage of umbilical cord blood and cord tissue for families, intended for potential future medical treatments and therapies.
- Stem Cells Preservation Preservation services for perinatal cells and tissues, including umbilical cord blood, cord tissue, and placenta tissue, offered to expectant parents and families.
- Expanded Access Programme Program providing access to stem cell therapies for patients outside of standard clinical trials, including therapies for conditions such as autism spectrum disorder.
- CDMO Services for Business Partners Contract Development and Manufacturing Organization services for cell therapy ATIMPs, including process development and optimization, tech transfer, cGMP manufacturing, cell/tissue sourcing, analytics, and global logistics, offered to biotech companies, pharmaceutical firms, and clinics.
- Stem Cells Banking for Society Stem cell banking services focused on societal benefit and accessibility for broader populations beyond standard family banking offerings.
Quantifiable outcome
- Over 260 cord blood transplantations or infusions enabled
- +2 more outcomes
Companies that use FamiCord Group
Customer profileSegments3 records
Ideal customer profiles3 records
FamiCord Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
FamiCord Group partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights5 records
FamiCord Group competitors and assessment
Company assessmentDirect peers
- Vita34 AG: Vita34 is a leading German/Austrian stem cell bank offering umbilical cord blood and tissue storage services, and a direct competitor in FamiCord's home German-speaking market; it also appears as a partner/regional brand on FamiCord's homepage.
- Cryo-Cell International: Cryo-Cell is one of the largest private family cord blood banks globally, offering a directly comparable consumer cord blood and tissue banking service with subscription-based storage fees in overlapping model.
- ViaCord (Revvity): ViaCord is a US family cord blood and tissue bank (now part of Revvity/PerkinElmer) that competes head-to-head on the same consumer-preservation value proposition and storage-economics model as FamiCord.
- Cord Blood Registry (CBR): CBR is among the largest US family cord blood banks, offering nearly identical services (collection kit, processing, long-term storage) and serving the same consumer segment as FamiCord's family banking business.
- Crioestaminal: Crioestaminal is a Portuguese family cord blood bank referenced as a FamiCord regional partner on the homepage, operating the same consumer stem cell banking model in Iberia.
- Biogenis: Biogenis is a Romanian stem cell bank listed as a FamiCord regional partner in Romania, offering a near-identical family cord blood banking proposition and competing within a shared network.
- Cellaviva: Cellaviva is a Scandinavian family stem cell bank listed as a FamiCord partner on the homepage, providing directly comparable cord blood and tissue storage services in Sweden and Denmark.
Broad incumbents
- Lonza Group: Lonza is a global CDMO with a sizable cell and gene therapy services franchise that overlaps with FamiCord's CDMO ATIMP offering; broader portfolio but directly competes for biotech cell therapy manufacturing contracts.
- Catalent: Catalent is a large CDMO with cell therapy capabilities (Paragon) that competes for similar biotech development and manufacturing engagements as FamiCord's business-to-business arm.
- Charles River Laboratories: Charles River provides cell and gene therapy CDMO services including process development and cGMP manufacturing, overlapping with the manufacturing services FamiCord offers biotech clients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
FamiCord Group social profiles
Digital presenceFamiCord Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
FamiCord Group leadership team
Management profileNumber of profiles
Profiles1 record
FamiCord Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FamiCord Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FamiCord Group
What does FamiCord Group do?
FamiCord Group is Europe's leading stem cell bank, collecting, processing, testing, and cryogenically storing umbilical cord blood, cord tissue, and placenta tissue for families. The company also operates as a Contract Development and Manufacturing Organization (CDMO) for biotech companies and clinics, providing process development, tech transfer, cGMP manufacturing, analytics, and global logistics for cell therapy Advanced Therapy Medicinal Products (ATIMPs).
When was FamiCord Group founded?
FamiCord Group was founded in 2002. It employs 101 to 250 people.
Where is FamiCord Group based?
FamiCord Group is headquartered in Warsaw, Poland, in the Europe region.
How does FamiCord Group make money?
Three revenue lines are on record. Family Stem Cell Banking Services are the primary driver. The others are CDMO Services for Biotech and Pharma and expanded Access Programme.
Who are FamiCord Group's main competitors?
Direct peers on record are Vita34 AG, Cryo-Cell International, ViaCord (Revvity), Cord Blood Registry (CBR), Crioestaminal, Biogenis and Cellaviva. Broad incumbents are Lonza Group, Catalent and Charles River Laboratories.
Does FamiCord Group have an API?
No public API is recorded for FamiCord Group.
What industry is FamiCord Group in?
FamiCord Group's product category is Stem Cell Banking and Cell Therapy Services. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 621991 and its SIC code is 2836.